| The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors SB Willingham, JP Volkmer, AJ Gentles, D Sahoo, P Dalerba, SS Mitra, ... Proceedings of the National Academy of Sciences 109 (17), 6662-6667, 2012 | 1760 | 2012 |
| Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma B Edris, K Weiskopf, AK Volkmer, JP Volkmer, SB Willingham, ... Proceedings of the National Academy of Sciences 109 (17), 6656-6661, 2012 | 318 | 2012 |
| Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers AL Brunner, AH Beck, B Edris, RT Sweeney, SX Zhu, R Li, K Montgomery, ... Genome biology 13 (8), 1-13, 2012 | 276 | 2012 |
| The macrophage colony-stimulating factor 1 response signature in breast carcinoma AH Beck, I Espinosa, B Edris, R Li, K Montgomery, S Zhu, S Varma, ... Clinical cancer research 15 (3), 778-787, 2009 | 234 | 2009 |
| Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling AH Beck, CH Lee, DM Witten, BC Gleason, B Edris, I Espinosa, S Zhu, ... Oncogene 29 (6), 845-854, 2010 | 159 | 2010 |
| ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour B Edris, I Espinosa, T Mühlenberg, A Mikels, CH Lee, SE Steigen, S Zhu, ... The Journal of pathology 227 (2), 223-233, 2012 | 104 | 2012 |
| Inactivation of the RB family prevents thymus involution and promotes thymic function by direct control of Foxn1 expression PM Garfin, D Min, JL Bryson, T Serwold, B Edris, CC Blackburn, ... Journal of Experimental Medicine 210 (6), 1087-1097, 2013 | 74 | 2013 |
| Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth B Edris, SB Willingham, K Weiskopf, AK Volkmer, JP Volkmer, ... Proceedings of the National Academy of Sciences 110 (9), 3501-3506, 2013 | 63 | 2013 |
| CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis I Espinosa, B Edris, CH Lee, HW Cheng, CB Gilks, Y Wang, ... The American journal of pathology 179 (4), 2100-2107, 2011 | 49 | 2011 |
| A role for versican in the development of leiomyosarcoma PA Keire, SL Bressler, JM Lemire, B Edris, BP Rubin, M Rahmani, ... Journal of Biological Chemistry 289 (49), 34089-34103, 2014 | 36 | 2014 |
| The epidemiology of desmoid tumors in Denmark M Anneberg, HML Svane, J Fryzek, G Nicholson, JB White, B Edris, ... Cancer Epidemiology 77, 102114, 2022 | 31 | 2022 |
| Comparative Gene Expression Profiling of Benign and Malignant Lesions Reveals Candidate Therapeutic Compounds for Leiomyosarcoma B Edris, JA Fletcher, RB West, M van de Rijn, AH Beck Sarcoma 2012, 2012 | 25 | 2012 |
| Compositions of antibody construct-agonist conjugates and methods of use thereof PA Thompson, B Edris US Patent App. 15/173,075, 2017 | 20 | 2017 |
| Compositions of antibody construct-agonist conjugates and methods of use thereof PA Thompson, B Edris US Patent App. 15/624,441, 2017 | 19 | 2017 |
| Abstract CT031: A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF … AM Schram, V Subbiah, R Sullivan, R Cosman, J Liu, EI Sbar, T Hoang, ... Cancer Research 83 (8_Supplement), CT031-CT031, 2023 | 13 | 2023 |
| Flipping the script on macrophages in leiomyosarcoma B Edris, K Weiskopf, IL Weissman, M van de Rijn OncoImmunology 1 (7), 1202-1204, 2012 | 10 | 2012 |
| A comparison of the Oligomap and TargetScan algorithms for miRNA target analysis B Edris Bmi231. stanford. edu, 2011 | 10 | 2011 |
| Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in … B Solomon, B Gao, V Subbiah, M Millward, L Rosen, J Desai, EI Sbar, ... Cancer Res 83, CT033, 2023 | 9 | 2023 |
| Antibody conjugates of immune-modulatory compounds and uses thereof PA Thompson, B Edris, CA Coburn, PR Baum, V Odegard WO Patent App. WO2018227018A1, 2018 | 9 | 2018 |
| Analysis and Targeting of ROR2 in Cancer R Nusse, B Edris US Patent 20,140,322,234, 2014 | 6 | 2014 |
Matt van de RijnProfessor of Pathology, Stanford UniversityAdresse e-mail validée de stanford.edu